	US 12,215,133 B2
	GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
Jiandong Yuan, Jiangsu (CN); Yunsong Song, Jiangsu (CN); Wenteng Zhen, Jiangsu (CN); Yue Cai, Jiangsu (CN); Jianing Gu, Jiangsu (CN); and Yangqing Huang, Jiangsu (CN)
Assigned to BrightGene Bio-Medical Technology Co., Ltd., Suzhou (CN); and BRIGHTGENE PHARMACEUTICAL (SUZHOU) CO. LTD., Suzhou (CN)
Filed by BrightGene Bio-Medical Technology Co., Ltd., Jiangsu (CN); and BRIGHTGENE PHARMACEUTICAL (SUZHOU) CO. LTD., Jiangsu (CN)
Filed on Dec. 14, 2023, as Appl. No. 18/540,219.
Application 18/540,219 is a continuation of application No. 18/283,164, previously published as PCT/CN2022/082552, filed on Mar. 23, 2022.
Claims priority of application No. 202110321851.6 (CN), filed on Mar. 25, 2021; and application No. 202110553745.0 (CN), filed on May 20, 2021.
Prior Publication US 2024/0150425 A1, May 9, 2024
Int. Cl. C07K 14/605 (2006.01); A61K 38/00 (2006.01); A61P 3/10 (2006.01)

CPC C07K 14/605 (2013.01) [A61P 3/10 (2018.01); A61K 38/00 (2013.01)]

8 Claims

1. A compound represented by any one of the following formulas I-3 or I-4 or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, isotopically labeled compound or prodrug thereof: